MarketWatch reported that while the Democratic-controlled US House of Representatives may pass Speaker Nancy Pelosi's Lower Drug Costs Now Act by the end of this month, analysts say the bill still is not likely to get past the Republican-run Senate and President Donald Trump.
Pelosi on Thursday said Democratic lawmakers are on track to be "well on our way to reconciling different versions and bringing something to the floor."
However, Pelosi's decision last month to launch an impeachment inquiry into Trump has helped reinforce predictions that a divided Washington will not be able to make major progress this year on curbing drug prices or other bipartisan issues, the news source said.
The measure is "dead on arrival on arrival in the Republican-controlled Senate," commented analysts at Height Capital Markets, while Beacon Policy Advisors predicted that it "will become a key messaging tool for Democrats as they look to contrast their accomplishments, particularly on healthcare, with President Trump."
Beacon's analysts added that "the president will look to punch back against the perception of inaction by releasing his own drug-pricing proposals, including one to allow importation and the International Pricing Index for drugs in Medicare Part B and certain of the most expensive drugs without competition in Part D."
To read more NewsPoints articles, click here.